Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KB304 · 1 trial · 3 indications
Treatment related adverse events as assessed by CTCAE
| Arm | Type | Description |
|---|---|---|
| KB304 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| KB304 | BIOLOGICAL | Genetically modified herpes simplex type 1 virus |
| 0.9% Normal Saline (NS) | DRUG | Placebo |
Inclusion Criteria: * Female in good general health, as determined by the Investigator, aged ≥18 and ≤75 at the time of consent. * Presence of moderate to severe dynamic wrinkles in the décolleté Target Area, as determined by the Investigator on the JDWS. * A Fitzpatrick skin phototype score of I-I...
KB304 is an investigational monoclonal antibody being studied for the treatment of wrinkles in the décolletage, the chest area. It is also being evaluated for pigmentation and décolleté wrinkles. The drug is in Phase 1 clinical development for this dermatological indication.
KB304 is a monoclonal antibody, but its specific molecular target has not been disclosed. The drug is being studied for its effects on wrinkles and pigmentation in the décolletage area, though the exact biological mechanism of action is not publicly detailed.
KB304 is being developed by Krystal Biotech, Inc., a biopharmaceutical company. The company is listed on the stock exchange under the ticker symbol KRYS. Krystal Biotech is conducting clinical trials to evaluate the safety and efficacy of KB304.
KB304 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The drug is being studied in an early-stage clinical trial to assess its safety and preliminary effectiveness.
KB304 is being evaluated in a Phase 1 clinical trial with the identifier NCT06724900. This study is assessing the treatment of wrinkles in women and is currently active but not recruiting participants. The trial is randomized, double-blind, and placebo-controlled, with an enrollment of 19 participants.
KB304 is the primary name for this investigational drug. No alternative names have been disclosed for this asset. It is a distinct monoclonal antibody being developed by Krystal Biotech for the treatment of wrinkles in the décolletage area.